Cytoreductive radical prostatectomy (cRP) is currently tested in patients with low-volume
metastatic hormone-sensitive prostate cancer (mHSPC). We aimed to review the literature …

Background: Previously considered inoperable patients (borderline resectable, locally
advanced, synchronous oligometastatic or metachronous pancreatic adenocarcinoma …

Background De novo oligometastatic prostate cancer (omPCa) on prostate-specific
membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and …

Background Patients with oligometastatic disease (OMD) treated with metastasis-directed
definitive local therapy such as stereotactic body radiotherapy (SBRT) are at risk of …

Background and introduction Growing evidence supports a combined modality treatment
strategy for patients with oligometastatic disease. However, lack of phase III trial data and …

Background Small retrospective series suggest that local consolidative treatment (LCT) may
improve survival in oligometastatic pancreatic ductal adenocarcinoma (PDAC). However, no …

Purpose This joint guideline by American Society for Radiation Oncology (ASTRO) and the
European Society for Radiotherapy and Oncology (ESTRO) was initiated to review evidence …

While the benefits of early palliative care for patients with metastatic cancer are well
established, cancer survivorship remains inadequately integrated into the care of patients …

(1) Background: Local therapy is highly promising in a multimodal approach strategy for
patients with low-volume metastatic prostate cancer (mPCa). We aimed to systematically …

Abstract Background and Purpose Current radiotherapy guidelines rely heavily on imaging-
based monitoring. Liquid biopsy monitoring promises to complement imaging by providing …